149 related articles for article (PubMed ID: 25246521)
1. Triptan use in Italy: Insights from administrative databases.
Da Cas R; Nigro A; Terrazzino S; Sances G; Viana M; Tassorelli C; Nappi G; Cargnin S; Pisterna A; Traversa G; Genazzani AA
Cephalalgia; 2015 Jun; 35(7):619-26. PubMed ID: 25246521
[TBL] [Abstract][Full Text] [Related]
2. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
[TBL] [Abstract][Full Text] [Related]
3. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
Zebenholzer K; Gall W; Wöber C
J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
[TBL] [Abstract][Full Text] [Related]
4. Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse.
Westergaard ML; Hansen EH; Glümer C; Jensen RH
Eur J Clin Pharmacol; 2015 Jul; 71(7):851-60. PubMed ID: 25967539
[TBL] [Abstract][Full Text] [Related]
5. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people.
Dekker F; Wiendels NJ; de Valk V; van der Vliet C; Knuistingh Neven A; Assendelft WJ; Ferrari MD
Cephalalgia; 2011 Jun; 31(8):943-52. PubMed ID: 21593190
[TBL] [Abstract][Full Text] [Related]
6. Utilization of triptans in Sweden; analyses of over the counter and prescription sales.
von Euler M; Keshani S; Baatz K; Wettermark B
Pharmacoepidemiol Drug Saf; 2014 Dec; 23(12):1288-93. PubMed ID: 25044442
[TBL] [Abstract][Full Text] [Related]
7. Triptans: low utilization and high turnover in the general population.
Panconesi A; Pavone E; Franchini M; Mennuti N; Bartolozzi M; Guidi L; Banfi R
Cephalalgia; 2010 May; 30(5):576-81. PubMed ID: 19732070
[TBL] [Abstract][Full Text] [Related]
8. Public Drug Coverage and Its Impact on Triptan Use Across Canada: A Population-Based Study.
Amadio A; Lee K; Yao Z; Camacho X; Knowles S; Lay C; Paterson JM; Hunt J; Gomes T;
Headache; 2015; 55 Suppl 4():212-20. PubMed ID: 25754431
[TBL] [Abstract][Full Text] [Related]
9. Triptan persistency among newly initiated users in a pharmacy claims database.
Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
[TBL] [Abstract][Full Text] [Related]
10. Triptan use and risk of cardiovascular events: a nested-case-control study from the French health system database.
Lugardon S; Roussel H; Sciortino V; Montastruc JL; Lapeyre-Mestre M
Eur J Clin Pharmacol; 2007 Aug; 63(8):801-7. PubMed ID: 17576547
[TBL] [Abstract][Full Text] [Related]
11. Patterns of triptans use: a study based on the records of a community pharmaceutical department.
Pavone E; Banfi R; Vaiani M; Panconesi A
Cephalalgia; 2007 Sep; 27(9):1000-4. PubMed ID: 17681022
[TBL] [Abstract][Full Text] [Related]
12. [Patterns of prescription and usage of triptans in Alsace (France): misuse is frequent and avoidable].
Perearnau P; Vuillemet F; Schick J; Weill G
Rev Neurol (Paris); 2006 Mar; 162(3):347-57. PubMed ID: 16585890
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study.
Schwedt TJ; Alam A; Reed ML; Fanning KM; Munjal S; Buse DC; Dodick DW; Lipton RB
J Headache Pain; 2018 May; 19(1):38. PubMed ID: 29797100
[TBL] [Abstract][Full Text] [Related]
14. Predictors of adherence to triptans: factors of sustained vs lapsed users.
Cady RK; Maizels M; Reeves DL; Levinson DM; Evans JK
Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
[TBL] [Abstract][Full Text] [Related]
15. Association of RAMP1 rs7590387 with the risk of migraine transformation into medication overuse headache.
Cargnin S; Pautasso C; Viana M; Sances G; Mittino D; Cantello R; Tassorelli C; Nappi G; Terrazzino S
Headache; 2015 May; 55(5):658-68. PubMed ID: 25881990
[TBL] [Abstract][Full Text] [Related]
16. Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.
Frisk P; Sporrong SK; Ljunggren G; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2016 Jun; 72(6):747-54. PubMed ID: 26922586
[TBL] [Abstract][Full Text] [Related]
17. Medication-overuse headache.
Tepper SJ
Continuum (Minneap Minn); 2012 Aug; 18(4):807-22. PubMed ID: 22868543
[TBL] [Abstract][Full Text] [Related]
18. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
[TBL] [Abstract][Full Text] [Related]
19. Identifying the factors underlying discontinuation of triptans.
Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
[TBL] [Abstract][Full Text] [Related]
20. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
